Clinical trials: HIV I Infection
HIV Infections
HIV Vaccine Designed for HIV Infected Adults Taking Anti-HIV Drugs
This study will evaluate the safety of and immune responses to a dendritic cell vaccination for HIV-1 infection. The vaccine will be made from a patient's own cells combined with small fragments of HIV-1 (made synthetically in a…
- Trial name
- NCT00056758
- Testing
- Autologous Dendritic Cell HIV Vaccination
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1 Infection, HIV Infections
Plasma and Intracellular Concentrations of Raltegravir and Etravirine Administered Once Daily
Hypothesis: the intracellular concentrations of raltegravir (RAL) and etravirine (ETV) administrated as 800 and 400 mg once a day, respectively, are similar to those obtained with the standard doses of 400 and 200 mg/12h…
- Trial name
- RAET (NCT01121809)
- Testing
- Raltegravir, Etravirine
- Where
- Spain
- Volunteers
- 16 people
- Sponsor
- Hospitales Universitarios Virgen del Rocío
HIV Infections
A Study of a Combination of Four Drugs in Patients With Recent HIV Infection
The purpose of this study is to see if it is safe to give a combination of four anti-HIV drugs to patients recently infected with HIV who have never received anti-HIV treatment.
- Trial name
- NCT00002233
- Testing
- Indinavir sulfate, Abacavir sulfate, Amprenavir
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Glaxo Wellcome
HIV (Human Immunodeficiency Virus), HIV -1 Infection
Combining Latency Reversing Agents to Address the HIV Reservoir
The PLUTO trial aims to contribute to the worldwide search for a functional cure of HIV. One the strategies ("shock and kill' strategy) aims to reverse the HIV-reservoir from latency by increasing cell-associated HIV-RNA, which…
- Trial name
- PLUTO (NCT07384624)
- Testing
- Pyrimethamine (PYR), Lenalidomide, Topiramate (drug)
- Where
- 4 sites in Netherlands
- Volunteers
- 30 people
- Sponsor
- Erasmus Medical Center
HIV Infections
Antiviral Activity of Peg-IFN-Alpha-2A in Chronic HIV-1 Infection
The objective of the study is to compare two different doses of Peg-INF-α-2A (90 or 180 ug/wk) for their ability to maintain viral control when initiated 5 weeks before ART (antiretroviral therapy) interruption in HIV positive…
- Trial name
- NCT00594880
- Testing
- Pegylated Interferon-alpha 2a, 180 mcg/week sc, Pegylated Interferon-alpha 2a, 90 mcg/week sc
- Where
- 5 sites in United States
- Volunteers
- 23 people
- Sponsor
- The Wistar Institute
HIV-1-infection
The Role of Home Packs of HIV PEPSE in High Risk Individuals
The study is looking at a new way to reduce the risk of catching HIV. Post-exposure Prophylaxis for sexual exposure (PEPSE) is where a month of HIV drugs can be given to reduce the chance of getting HIV, after a risk.
- Trial name
- Home PEPSE (NCT04965662)
- Testing
- Maraviroc, Truvada
- Where
- United Kingdom
- Volunteers
- 139 people, healthy volunteers welcome
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
HIV-1-infection
Study to Evaluate Efficacy and Safety of Switching to VM-1500A-LAI + 2NRTIs From the 1st Line Standard of Care Therapy
Multicenter, open-label, randomized, active control study to evaluate efficacy and safety of switching to VM-1500A-LAI + 2NRTIs from the 1st line standard of care therapy for 48 weeks.
- Trial name
- NCT05204394
- Testing
- VM-1500A-LAI, Standard of Care
- Where
- 2 sites in Russia
- Volunteers
- 438 people
- Sponsor
- Viriom
HIV Infections
Safety and Immune Response to Vicriviroc in Combination Regimens in HIV-Infected ART Experienced Children and Adolescents
Complications with current HIV antiretroviral therapy have left many children and adolescents with limited therapeutic options due to drug resistance.
- Trial name
- NCT00766597
- Testing
- Vicriviroc
- Where
- 9 sites in United States, Puerto Rico
- Volunteers
- 9 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are widely used as part of combination antiretroviral therapy (ART) for infants and children, but NNRTI resistance is increasing, leading to treatment failure.
- Trial name
- NCT01504841
- Testing
- Etravirine (ETR)
- Where
- 11 sites in United States, Brazil and 1 more
- Volunteers
- 26 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, HIV Seronegativity
Daily Tenofovir DF to Prevent HIV Infection Among Sex Workers in Cambodia
Tenofovir disoproxil fumarate (also known as tenofovir DF or Viread) is used with other anti-HIV drugs to treat HIV infection. Taking tenofovir DF every day may also prevent HIV infection.
- Trial name
- NCT00078182
- Testing
- Tenofovir DF
- Where
- Cambodia
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic HIV-1 Infection
Towards HIV Functional Cure
During the ERAMUNE-01 and -02 studies, the HIV-DNA quantification in the PBMCs (Peripheral Blood Mononuclear Cells) showed showed that some patients had a very low or undetectable reservoir.
- Trial name
- ULTRASTOP (NCT01876862)
- Testing
- Antiretroviral treatment interruption
- Where
- 2 sites in France
- Volunteers
- 15 people
- Sponsor
- Objectif Recherche Vaccins SIDA
HIV Infection, Renal Function Disorder
Utility of Urinary beta2 Microglobulin as an Early Marker of Renal Dysfunction in Vietnamese HIV-Infected Patients
This study is to investigate clinical utility of beta2 microglobulin as an early marker for renal dysfunction caused by Tenofovir in Vietnamese HIV-infected patients.
- Conditions
- HIV Infection, Renal Function Disorder, Renal Tubular Disorder
- Trial name
- NCT02256579
- Volunteers
- 1,800 people
- Sponsor
- National Center for Global Health and Medicine, Japan
HIV Infections
Molecular Diversity of HIV-1 Group O Strains and Treatment Management in Cameroon
Infections with HIV-1 group O are found in 1 to 3 % of persons living with HIV in Cameroon. The natural history and treatment response is not well understood.
- Trial name
- NCT00658346
- Testing
- Treatment initiation for HIV-1 group O infected patients, Treatment initiation for HIV-1 group M infected patients
- Where
- 2 sites in Cameroon
- Volunteers
- 141 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Immunization; Infection, Pertussis
Pertussis Immunization During Pregnancy & HIV Infection
The impact of chronic HIV infection and pregnancy on different aspects of the humoral response to pertussis immunization with the TDaP vaccine will be studied.
- Conditions
- Immunization; Infection, Pertussis, HIV-1-infection, Pregnancy
- Trial name
- NCT03519373
- Testing
- TDaP
- Where
- 2 sites in Belgium
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Saint Pierre
HIV-1 Infection, Receipt of Cal-1 Modified Hematopoietic Cellular Products
Long Term Follow up for the Detection of Delayed Adverse Events in Cal-1 Recipients
Long term safety follow-up of Cal-1 recipients
- Trial name
- NCT02390297
- Testing
- Blood tests
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Calimmune, Inc.
HIV Infections
The Safety and Effectiveness of PMPA Prodrug in HIV-Infected Patients
To evaluate the safety of single and multiple doses (28 daily doses) of 9-[2-(R)-[[bis[[(isopropoxycarbonyl)- oxy]methoxy]phosphinoyl]methoxy]propyl]adenine fumarate (PMPA) prodrug administered orally to HIV-infected patients.
- Trial name
- NCT00002396
- Testing
- Tenofovir disoproxil fumarate
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Gilead Sciences
HIV Infections
TMC114-TiDP3-C182 - A Study to Compare the Oral Bioavailability of a 800 mg Prototype Tablet Formulation of Darunivar (DRV) to That of the 400 mg Commercial Tablet Formulation in the Presence of Low Dose Ritonavir, Under Fasted and Fed Conditions
The purpose of this study is to compare the drug levels of darunavir obtained after administration of a single administration of the 800 mg tablet (new formulation) to that following administration of two 400 mg commercial…
- Trial name
- NCT01052883
- Testing
- DRV commercial formulation/ DRV new formulation/ rtv 100mg tab
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV-1 Infection
Evaluation of Safety, Tolerability, Pharmacokinetics, and Antiretroviral Activity of Ulonivirine (MK-8507) in Human Immunodeficiency Virus (HIV-1)-Infected Participants (MK-8507-003)
The study will evaluate the safety, tolerability, pharmacokinetics, and antiretroviral activity of a single dose of ulonivirine in antiretroviral therapy (ART)-naive, HIV-1 infected participants.
- Trial name
- NCT02174159
- Testing
- Ulonivirine
- Volunteers
- 18 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV-1-infection
ANRS 12406 EvvA Study
ANRS 12406 EvvA is an observational, longitudinal and monocentric study evaluating the virological success rate in HIV-infected adolescents on antiretroviral therapy in Cameroon.
- Trial name
- EvvA (NCT04593979)
- Where
- Cameroon
- Volunteers
- 289 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections
Autologous Dendritic Cell Vaccine in HIV1 Infection
This study aims to look at the safety and tolerability of immunization with dendritic cell vaccine prepared using the patient's own cells and virus.
- Trial name
- NCT00510497
- Testing
- Autologous HIV-1 ApB DC Vaccine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Sharon Riddler